[go: up one dir, main page]

PE20120577A1 - Anticuerpos contra la proteina tweak humana y usos de los mismos - Google Patents

Anticuerpos contra la proteina tweak humana y usos de los mismos

Info

Publication number
PE20120577A1
PE20120577A1 PE2011001689A PE2011001689A PE20120577A1 PE 20120577 A1 PE20120577 A1 PE 20120577A1 PE 2011001689 A PE2011001689 A PE 2011001689A PE 2011001689 A PE2011001689 A PE 2011001689A PE 20120577 A1 PE20120577 A1 PE 20120577A1
Authority
PE
Peru
Prior art keywords
sequence
antibodies against
against human
human tweak
tweak protein
Prior art date
Application number
PE2011001689A
Other languages
English (en)
Inventor
Monika Baehner
Hendrik Knoetgen
Jens Niewoehner
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20120577A1 publication Critical patent/PE20120577A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

UNION DE ANTICUERPO A TWEAK HUMANA, CRACTERIZADO PORQUE COMPRENDE CDR1H DE SEC ID Nº 6, 14, 22; CDR2H DE SECUENCIA SEC ID Nº7, 15, 23, 74; CDR3H DE SECUENCIA SEC ID Nº8, 16, 24 Y CDR1L DE SECUENCIA SEC ID Nº2, 10, 18; CDR2L DE SECUENCIA SEC ID Nº 3, 11, 19; CDR3L DE SECUENCIA SEC ID Nº4, 12, 20; ENTRE OTROS. DICHO ANTICUERPO ES UTIL EN EL TRATAMIENTO DE CANCER DE COLON, PULMON O DE PANCREAS
PE2011001689A 2009-04-02 2010-03-30 Anticuerpos contra la proteina tweak humana y usos de los mismos PE20120577A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09004905 2009-04-02

Publications (1)

Publication Number Publication Date
PE20120577A1 true PE20120577A1 (es) 2012-05-23

Family

ID=40673340

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011001689A PE20120577A1 (es) 2009-04-02 2010-03-30 Anticuerpos contra la proteina tweak humana y usos de los mismos

Country Status (23)

Country Link
US (3) US8093006B2 (es)
EP (2) EP2414398A2 (es)
JP (1) JP5596777B2 (es)
KR (1) KR101344611B1 (es)
CN (1) CN102369219A (es)
AR (1) AR076020A1 (es)
AU (1) AU2010233997A1 (es)
BR (1) BRPI1014867A2 (es)
CA (1) CA2756245A1 (es)
CL (1) CL2011002452A1 (es)
CO (1) CO6362025A2 (es)
CR (1) CR20110462A (es)
EC (1) ECSP11011362A (es)
IL (1) IL214355A0 (es)
MA (1) MA33097B1 (es)
MX (1) MX2011010117A (es)
NZ (1) NZ594347A (es)
PE (1) PE20120577A1 (es)
RU (1) RU2011143903A (es)
SG (2) SG10201404107SA (es)
TW (1) TWI423815B (es)
UA (1) UA105520C2 (es)
WO (1) WO2010115555A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8093006B2 (en) * 2009-04-02 2012-01-10 Hoffmann-La Roche Inc. Antibodies against human tweak and uses thereof
US9526846B2 (en) 2009-08-19 2016-12-27 Safety Syringes, Inc. Patient-contact activated needle stick safety device
WO2011097500A2 (en) 2010-02-04 2011-08-11 University Of Louisville Research Foundation, Inc. The tweak/fn14 system regulates skeletal muscle atrophy and regeneration
SG188605A1 (en) 2010-10-05 2013-04-30 Hoffmann La Roche Antibodies against human tweak and uses thereof
EP2683740B1 (en) 2011-03-10 2018-07-04 Omeros Corporation Generation of anti-fn14 monoclonal antibodies by ex-vivo accelerated antibody evolution
PE20142422A1 (es) 2012-04-05 2015-01-21 Hoffmann La Roche Anticuerpos biespecificos contra tweak humana e il 17 humana y usos de los mismos
JP2016000003A (ja) * 2013-04-19 2016-01-07 アステラス製薬株式会社 新規抗ヒトｔｗｅａｋ抗体
CN103399151A (zh) * 2013-06-24 2013-11-20 上海交通大学医学院附属瑞金医院 Cxcl8细胞因子检测试剂在制备甲状腺乳头状癌的诊断试剂中的应用
JP7415939B2 (ja) * 2018-10-31 2024-01-17 アステラス製薬株式会社 抗ヒトＦｎ１４抗体
WO2025005938A1 (en) * 2023-06-26 2025-01-02 Memorial Sloan-Kettering Cancer Center Antibodies and antigen binding fragments thereof binding to chimeric receptors and uses thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
US7129061B1 (en) 1996-08-07 2006-10-31 Biogen Idec Ma Inc. Tumor necrosis factor related ligand
EA003187B1 (ru) 1996-08-07 2003-02-27 Байоджен, Инк. Лиганд, родственный фактору некроза опухоли
JP2001513626A (ja) 1997-02-12 2001-09-04 アボツト・ラボラトリーズ 疾患の治療及び診断のために有用なｔｎｆファミリーのメンバー
ES2258817T3 (es) 1997-05-21 2006-09-01 Biovation Limited Metodo para la produccion de proteinas no inmunogenas.
CA2305713A1 (en) 1997-10-10 1999-04-22 Genentech, Inc. Apo-3 ligand
AU2507700A (en) 1999-01-15 2000-08-01 Biogen, Inc. Antagonists of tweak and of tweak receptor and their use to treat immunological disorders
EP1166550A4 (en) 1999-03-04 2005-09-14 Vision Sciences Inc Image sensor's unit cell with individually controllable electronic shutter circuit
GB9922069D0 (en) 1999-09-17 1999-11-17 Technolog Ltd Water distribution pressure control method and apparatus
WO2001030374A1 (en) 1999-10-22 2001-05-03 The University Of Pittsburgh Stem cell engraftment-enhancing cellular proteins and their uses
AU8028400A (en) 1999-10-22 2001-05-08 Scimed Life Systems, Inc. Guided injection device
AU782067B2 (en) 1999-12-20 2005-06-30 Immunex Corporation TWEAK receptor
US6943146B2 (en) 2000-05-08 2005-09-13 Biogen Idec Ma Inc. Method for promoting neovascularization
US7208151B2 (en) 2001-09-12 2007-04-24 Biogen Idec Ma Inc. Tweak receptor agonists as anti-angiogenic agents
SI1997512T1 (sl) 2002-04-09 2014-03-31 Biogen Idec Ma Inc. Postopki za zdravljenje stanj, povezanih s TWEAK-om
WO2006052926A2 (en) 2004-11-08 2006-05-18 University Of Maryland, Baltimore Tweak as a therapeutic target for treating central nervous system diseases associated with cerebral edema and and cell death
US7939490B2 (en) 2004-12-13 2011-05-10 University Of Maryland, Baltimore TWEAK as a therapeutic target for treating central nervous system diseases associated with cerebral edema and cell death
DK2529619T3 (en) 2005-02-17 2016-01-11 Biogen Ma Inc Treatment of neurological disorders
WO2006088890A2 (en) 2005-02-17 2006-08-24 Biogen Idec Ma Inc. Treating stroke
CN101171035A (zh) 2005-03-07 2008-04-30 健泰科生物技术公司 用于调控tweak和fn14活性的方法和组合物
CA2607697C (en) 2005-05-10 2015-01-06 Biogen Idec Ma Inc. Treating and evaluating inflammatory disorders
EP2460832A3 (en) * 2005-05-27 2012-10-31 Biogen Idec MA Inc. TWEAK binding antibodies
WO2006130429A2 (en) 2005-05-27 2006-12-07 Biogen Idec Ma Inc. Treatment of cancer
US8093006B2 (en) * 2009-04-02 2012-01-10 Hoffmann-La Roche Inc. Antibodies against human tweak and uses thereof

Also Published As

Publication number Publication date
KR20110122868A (ko) 2011-11-11
WO2010115555A2 (en) 2010-10-14
BRPI1014867A2 (pt) 2016-04-12
AR076020A1 (es) 2011-05-11
US8852887B2 (en) 2014-10-07
JP2012521771A (ja) 2012-09-20
SG175005A1 (en) 2011-11-28
NZ594347A (en) 2012-09-28
TW201039847A (en) 2010-11-16
AU2010233997A1 (en) 2011-08-18
SG10201404107SA (en) 2014-10-30
US20120083015A1 (en) 2012-04-05
CN102369219A (zh) 2012-03-07
CA2756245A1 (en) 2010-10-14
IL214355A0 (en) 2011-09-27
UA105520C2 (uk) 2014-05-26
MA33097B1 (fr) 2012-03-01
RU2011143903A (ru) 2013-05-10
KR101344611B1 (ko) 2013-12-30
CR20110462A (es) 2011-09-21
US8883976B2 (en) 2014-11-11
ECSP11011362A (es) 2011-10-31
US20120207750A1 (en) 2012-08-16
US8093006B2 (en) 2012-01-10
US20100255008A1 (en) 2010-10-07
JP5596777B2 (ja) 2014-09-24
WO2010115555A3 (en) 2011-01-06
EP2597104A1 (en) 2013-05-29
CL2011002452A1 (es) 2012-03-23
EP2414398A2 (en) 2012-02-08
MX2011010117A (es) 2011-10-14
TWI423815B (zh) 2014-01-21
CO6362025A2 (es) 2012-01-20

Similar Documents

Publication Publication Date Title
PE20120577A1 (es) Anticuerpos contra la proteina tweak humana y usos de los mismos
PE20121616A1 (es) Anticuerpos anti-her3
PE20110668A1 (es) Anticuerpos anti-linfopoyetina estromal timica (anti-tslp)
CY1117695T1 (el) Υψηλης συγγενειας ανθρωπινα αντισωματα κατα της ανθρωπινης αγγειοποιητινης-2
UY31862A (es) Inmunoglobulina con dominio variable dual y usos de la misma
MX2010004482A (es) Anticuerpos anti-proteina g vsr.
PE20120551A1 (es) Anticuerpos contra la angiopoyetina 2 humana
UY32603A (es) Inmunoglobulina con dominio variable dual y usos de la misma
PE20120622A1 (es) Anticuerpos anti-vegf y sus usos
PE20181054A1 (es) Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion
UA109633C2 (uk) Антитіло людини проти тканинного фактора
PE20140190A1 (es) Moduladores de proteinas notum y metodos de uso
UY33826A (es) Proteínas de unión con dominios trivariables y sus usos
PE20120562A1 (es) Anticuerpo anti-axl
CR20130351A (es) Anticuerpos monoclonales humanos para la quinasa-1 tipo receptor de activina (diviisional 9819)
WO2009013543A3 (en) Targeted binging agents directed to kdr and uses thereof - 035
PE20121552A1 (es) Anticuerpos monoclonales anti cea humanizados de afinidad madura
MX2014003832A (es) Molecula de union al antigeno que induce la inmunorespuesta al antigeno objetivo.
PE20090722A1 (es) Hepcidina, antagonistas de la hepcidina y metodos de uso
CY1117031T1 (el) Μονοκλωνικα αντισωματα εναντι claudin-18 στην αγωγη εναντι καρκινου
BR112013010857A2 (pt) imonoglubulinas de duplo domínio variável e usos das mesmas
PE20091352A1 (es) Composicion que comprende anticuerpo que se fija al dominio ii de her2, y sus variantes acidas
PE20130393A1 (es) Anticuerpos con union de antigenos dependiente de ph
CY1116842T1 (el) Ειδικα εξανθρωπισμενα αντισωματα στην πρωτοϊνιδιακη μορφη του βητα-αμυλοειδους πεπτιδιου
CR20120154A (es) Inmunoglobulinas con dominio variable dual y usos de las mismas

Legal Events

Date Code Title Description
FC Refusal